TACE with lenvatinib and immunotherapy for ruptured liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of targeted therapy (lenvatinib), immunotherapy (PD-1 inhibitor), and a procedure called TACE (which delivers chemotherapy directly to the liver tumor) for people whose liver cancer has ruptured. The goal is to stop bleeding and shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that has ruptured (caused bleeding around the liver)
- You have not had this specific combination of drugs or the TACE procedure before
- Your liver function is good to moderate (Child-Pugh class A or B)
- You are between 18 and 75 years old
- Your cancer has not spread to more than 5 spots in the body
- You have no history of other cancers or serious liver problems like hepatic encephalopathy or recent gastrointestinal bleeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a procedure called TIPS (which helps relieve pressure in the liver) with two drugs—lenvatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—for people with advanced liver cancer that has spread into the main vein of the liver. It aims to see if this combination can help control the cancer and improve symptoms.
This trial tests whether taking lenvatinib (a targeted pill) before a liver procedure called TACE can help people with large hepatocellular carcinoma (HCC) get better results while waiting for a liver transplant. It may help shrink or control the cancer without stopping transplant plans.
This trial tests a combination of liver-directed therapy (TACE) with two drugs—bevacizumab (Avastin) and atezolizumab (Tecentriq)—as a first treatment for liver cancer that cannot be removed by surgery. The goal is to see if this approach helps shrink tumors and control the disease longer.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests a combination of treatments for liver cancer that can be surgically removed. It adds immunotherapy drugs (Iparomlimab and Tuvonralimab, together called QL1706) and targeted therapy (Lenvatinib) to a procedure called TACE (chemoembolization) to see if this approach shrinks the tumor and lowers the chance of recurrence after surgery.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.